Get to know our clinical trials
Clinical trial of Sitravatinib in combination with Tislelizumab in patients with uveal metastatic melanoma with liver metastases
THE STUDY INVOLVES PATIENTS WITH METASTATIC UVEAL MELANOMA WITH LIVER METASTASES. ALL PATIENTS IN THE TRIAL WILL RECEIVE THE EXPERIMENTAL COMBINATION OF SITRAVATINIB AND TISLELIZUMAB. THE STUDY IS DIVIDED INTO 3 PHASES: VERIFICATION THAT PATIENTS FIT THE NECESSARY CRITERIA FOR PARTICIPATION, TREATMENT PERIOD AND POST-TREATMENT FOLLOW-UP.
Technical Summary
- PHASE II, OPEN-LABEL TRIAL TO EVALUATE THE PRELIMINARY EFFICACY OF SITRAVATINIB IN COMBINATION WITH TISLELIZUMAB IN PATIENTS WITH METASTATIC UVEAL MELANOMA WITH LIVER METASTASES. IMMUNOTHERAPY
- Code EudraCT: 2021-002474-99
- Protocol number: GEM-2101
- Promoter: GEM
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.